Latest Ipo And Capital Markets News

Page 1 of 1
Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.
Ada Torres
Ada Torres
25 Feb 2026
Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.
Ada Torres
Ada Torres
29 Jan 2026
Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.
Ada Torres
Ada Torres
31 Oct 2025
Infragreen Group Limited reported a robust 190% increase in revenue for FY25 following its successful IPO, despite a significant statutory net loss. The company’s strategic acquisitions and expanded ownership stakes underpin a promising outlook in sustainable infrastructure.
Nora Hopper
Nora Hopper
27 Aug 2025